Drugs by condition
Drugs approved for high triglycerides
Last checked: Nov 19, 2026Source: FDA labels (openFDA), Drugs@FDAMethods & limitations
Brand-name drugs approved
12
Still marketed, NDA or BLA
Drug classes
5
Novel drugs
7
New molecular entities and new biologics
In development
12
Investigational drugs in Phase 2 or 3
Newest approvals
The most recently first-approved brand-name drugs for high triglycerides.
- Redemplo (Plozasiran Sodium) · Arrowhead NovelBreakthrough therapyOrphanNov 18, 2025
- Tryngolza (Autoinjector) (Olezarsen Sodium) · Ionis Pharms INC NovelBreakthrough therapyPriority reviewOrphanDec 19, 2024
- Atorvaliq (Atorvastatin Calcium) · Cmp Dev LLC Feb 1, 2023
- Myalept (Metreleptin) · Chiesi Farmaceutici Spa NovelPriority reviewOrphanFeb 24, 2014
- Vascepa (Icosapent Ethyl) · Amarin Pharms Jul 26, 2012
All approved drugs for high triglycerides, by class
Every marketed NDA or BLA whose current FDA label names this condition in its Indications and Usage section, plus 174 generic labels. A drug can be approved for only part of a condition (one subtype or stage, or as add-on therapy), so check its label.
APOC-III-directed RNA Interaction (1)
- Redemplo Plozasiran Sodium · Arrowhead · 2025
Leptin Analog (1)
- Myalept Metreleptin · Chiesi Farmaceutici Spa · 2014
HMG-CoA Reductase Inhibitor (1)
- Zocor Simvastatin · Organon · 1991
Peroxisome Proliferator Receptor alpha Agonist (1)
- Antara (Micronized) Fenofibrate · Lupin · 2004
Class not listed in FDA's data (8)
- Tryngolza (Autoinjector) Olezarsen Sodium · Ionis Pharms INC · 2024
- Crestor Rosuvastatin Calcium · Astrazeneca · 2003
- Lipitor Atorvastatin Calcium · Upjohn · 1996
- Colestid Colestipol Hydrochloride · Pfizer · 1977
- Atorvaliq Atorvastatin Calcium · Cmp Dev LLC · 2023
- Vascepa Icosapent Ethyl · Amarin Pharms · 2012
- Caduet Amlodipine Besylate, Atorvastatin Calcium · Pharmacia · 2004
- Colestid Colestipol Hydrochloride · Pfizer · 1994
Drugs in development for high triglycerides
Investigational drugs FDA has not approved, in active or recent industry-sponsored Phase 2 and 3 trials for this condition. Phase 3 first.
- SHR-1918Phase 37 trials
Beijing Suncadia Pharmaceuticals Co., Ltd · Homozygous Familial Hypercholesterolemia, Hyperlipidemia, Hypercholesterolemia
- DR10624Phase 35 trials
Zhejiang Doer Biologics Co., Ltd. · Severe Hypertriglyceridemia, Hypertriglyceridemia, Severe Hypertriglyceridemia (sHTG)
- PegozaferminBIO89-100Phase 33 trials
Roche (Genentech) · Metabolic Dysfunction-Associated Steatohepatitis (MASH) / Nonalcoholic Steatohepatitis (NASH) With Compensated Cirrhosis, Metabolic Dysfunction-Associated Steatotic Liver Disease (MASH) / Nonalcoholic Steatohepatitis (NASH) With Fibrosis, Severe Hypertriglyceridemia
- MAR001Phase 23 trials
Marea Therapeutics · Hypertriglyceridemia
- RBD5044Phase 22 trials
Ribocure Pharmaceuticals AB · Dyslipidemias, Hypertriglyceridemia
- ION775Phase 21 trial
Ionis Pharmaceuticals · Hypertriglyceridemia, Severe Hypertriglyceridemia
- JMT202Phase 21 trial
Shanghai JMT-Bio Inc. · Hypertriglyceridemia
- MN-001Phase 21 trial
MediciNova · Diabetes Mellitus, Type 2, Hypertriglyceridemia, Non-Alcoholic Fatty Liver Disease
- NST-1024Phase 21 trial
NorthSea Therapeutics B.V. · High Triglycerides
- RDX-002Phase 21 trial
Response Pharmaceuticals · Triglycerides, Weight Gain Trajectory, Cholesterol, Elevated
- RN0361Phase 21 trial
Ikaria Bioscience Pty Ltd · Hypertriglyceridemia, Familial Chylomicronemia Syndrome
- SolbinsiranLY3561774Phase 21 trial
Eli Lilly · Severe Hypertriglyceridemia
1 discontinued brand-name drugs whose label still names it
- Tricor Fenofibrate
More on high triglycerides: recruiting trials · published research
Related in cardiovascular and metabolic: Type 2 diabetes · Type 1 diabetes · Obesity and weight management · High blood pressure (hypertension) · Heart failure · High cholesterol · Atrial fibrillation · Blood clots (DVT and pulmonary embolism) · Stroke prevention · Coronary artery disease and heart attack
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.